Alzheimers/Dementia Medical Cannabis Studies


• addiction (10)

• alzheimers/dementia (14)

• amyotrophic-lateral-sclerosis-als-lou-gehrigs (2)

• antibacterial (6)

• antioxidant (8)

• antiprion (1)

• anxiety (10)

• appetite (4)

• arthritis (4)

• asthma (1)

• attention-deficit-hyperactivity-disorder-adhd (5)

• autism (11)

• autoimmune (3)


• batten-disease (6)

• benefits (9)

• breast-cancer (7)


• cancer (94)

• cannabidiol-cbd (8)

• cardiovascular (8)

• cb1-receptor (8)

• cb2-receptor (9)

• cellular-function (4)

• cerebral-palsy (1)

• cognition (2)

• colon-cancer (8)


• d9-tetrahydrocannabinol-thc (4)

• d9-tetrahydrocannabinolic-acid-thca (1)

• diabetes (4)

• drug-interactions (2)


• emesis (6)

• endocannabinoid-system-ecs (45)

• endocrine-system (3)

• epilepsy (30)


• fibromyalgia (2)

• fibrosis (1)


• gastrointestinal-disease (6)

• general (20)

• glaucoma (1)

• glioblastoma (1)

• glioma (9)


• health-care (1)

• hiv (7)

• huntingtons-disease (1)


• immune-function (8)

• infant-development (1)

• inflammation (9)

• ischemia (3)


• krabbe-disease (4)


• liver (2)

• lung-cancer (2)

• lupus (1)


• memory (3)

• mental-illness (14)

• migraine (1)

• mitochondria (1)

• multiple-sclerosis (15)


• national-institute-on-drug-abuse-nida (1)

• nausea (1)

• nervous-system (4)

• neuro-protective-and-neuro-generative (7)


• pain (29)

• pancreatitis (1)

• prostate-cancer (2)


• schizophrenia (2)

• skin (1)

• sports (3)


• thc (1)

• therapeutic (1)

• traumatic-brain-injury-tbi (1)

• View All (505)
  • 9-Tetrahydrocannabinolic acid synthase production in Pichia pastoris enables chemical synthesis of cannabinoids (Page not found)

    View study

  • A Molecular Link Between the Active Component of Marijuana and Alzheimer's Disease Pathology (2008)

    THC competitively inhibits the enzyme acetylcholinesterase (AChE) and prevents the aggregation of amyloid ? peptide induced by AChE (A?), the key pathological marker of Alzheimer’s disease. View study

  • Activity of muscarinic, galanin and cannabinoid receptors in the prodromal and advanced stages in the triple transgenic mice model of Alzheimer's disease (2016)

    The positive regulation of the galaninnergic and endocannabinoid systems supports the hypothesis of their neuroprotective functions, which are established before clear clinical cognitive symptoms of Alzheimer’s disease appear. View study

  • Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease (2011)

    Based on the results of this study it was found that cannabidiol (CBD) has the ability to modulate the function of the microglial cell in vitro, inducing beneficial effects in an in vivo model of Alzheimer’s disease, thus indicating that CBD has the potential to represent a new therapeutic approach to treat this disease. View study

  • Cannabinoids and Dementia: A Review of Clinical and Preclinical Data (2010)

    Many studies show that cannabinoids are suitable for treating the symptoms of dementia, especially in in vitro tests, however, much more research and clinical trials are needed in vivo and in humans to corroborate them. View study

  • Cannabinoids for the treatment of dementia (2009)

    Cannabinoids may have more positive and specific effects on the disruption of the disease process in Alzheimer’s disease. View study

  • Cannabinoids for treatment of Alzheimer�s disease: moving toward the clinic (2014)

    The cannabinoid compounds have polyvalent properties for the treatment of Alzheimer’s disease, which together promote progress towards a clinical trial. View study

  • Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia (2006)

    Dronabinol reduces nocturnal motor activity and agitation in patients with severe dementia. Thus, it represents a great potential for the safe treatment of alterations in dementia. View study

  • Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview (2016)

    Properties and neuroprotective effects of the phytochemicals belonging to polyphenols, cannabinoids, alkaloids and isothiocyanates for the treatment and prevention of common types of dementia. View study

  • Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer�s disease (2016)

    This study was conducted on CB2R cannabinoid receptors (CB2R) in order to analyze their potential as therapeutic targets. It was found that CB2R has a general role of glucoregulation in the brain, which increases the therapeutic interest in CB2R agonists as nootropic agents. View study

  • Synthetic cannabinoids in dementia with agitation: case studies and literature review (2013)

    A synthetic cannabinoid known as Nabilone improved psychomotor agitation, aggression and communication in patients with dementia, thus demonstrating the potential of cannabinoids in the treatment of these disorders. View study

  • The influence of cannabinoids on generic traits of neurodegeneration (2013)

    Modulation of the cannabinoid system has shown beneficial effects and constitutes a possibility for the treatment of neurodegenerative disorders such as Parkinson’s disease. View study

  • The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer's disease (2014)

    In this study, we summarize the role of endocannabinoid signaling in Alzeimer disease and the probable mechanisms through which modulators of the endocannabinoid system provide their effects, thus highlighting how this objective could provide more advantages than other therapeutic objectives. View study

  • The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer's disease. (2017)

    Alzheimer’s disease (AD) is the most common neurodegenerative disorder, characterized by a progressive loss of cognition. The present review was focused on presenting a brief introduction to (AD) biology and current treatment options before outlining comprehensively phytocannabinoid cannabidiol (CBD) biology and pharmacology, followed by in-vitro and in-vivo evidence for the therapeutic potential of (CBD). View study